12
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T40051 |
Acid Ceramidase-IN-1
|
Others | Others |
Acid Ceramidase-IN-1 是一种可口服且具有良好的脑渗透性的酸性神经酰胺酶 (AC, ASAH-1) 抑制剂。Acid Ceramidase-IN-1 可用于研究神经系统疾病。 | |||
T75142 |
Acid Ceramidase-IN-2
|
Others | Others |
Acid Ceramidase-IN-2(compound 1)是一款针对酸性神经酰胺酶(ceramidase)的抑制剂,显示出抗增殖及细胞活性抑制的潜力。有研究表明,该化合物在前列腺癌细胞中可阻止人酸性神经酰胺酶的过度表达,从而揭示了其潜在的抗肿瘤能力。此外,Acid Ceramidase-IN-2被三种α-酮酰胺:GT85、GT98和GT99在体外有效抑制其水解作用。 | |||
T21658 |
ARN14974
|
Others | Others |
ARN14974 是一种有效的全身活性的胞内酸性神经酰胺酶抑制剂 (IC50=79 nM),是一种苯并恶唑酮甲酰胺化合物。 | |||
T1307 |
Carmofur
HCFU,卡莫氟 |
Nucleoside Antimetabolite/Analog; Virus Protease; SARS-CoV; DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Microbiology/Virology |
Carmofur (HCFU) 是 5-氟尿嘧啶的衍生物,是一种抗肿瘤药物。它是一种酸性神经酰胺酶抑制剂,用于治疗乳腺癌和结直肠癌。它抑制 SARS-CoV-2主要蛋白酶,还抑制 Vero E6 细胞 SARS-CoV-2,EC50为 24.3 μM。 | |||
T84964 |
SOBRAC
|
Others | Others |
SOBRAC, a derivative of the acid ceramidase inhibitor SABRAC, acts as an irreversible inhibitor of acid ceramidase (Ki= 29.7 nM). | |||
T84961 |
SOCLAC
N-chloroacetyl Sphingosine |
Others | Others |
SOCLAC, a derivative of the acid ceramidase inhibitor SABRAC, functions as an irreversible inhibitor of acid ceramidase with an inhibition constant (Ki) of 40.2 nM. | |||
T11835L |
LCL521 dihydrochloride
1,3DMG-B13 dihydrochloride |
Others | Others |
LCL521 dihydrochloride is a compound that functions as an inhibitor of both acid ceramidase (ACDase) and lysosomal acid sphingomyelinase (ASMase). | |||
T36468 |
ARN14988
|
Others | Others |
ARN14988 is a potent inhibitor of acid ceramidase (IC50 = 12.8 nM for the human enzyme). It inhibits acid ceramidase activity and increases levels of C16 dihydro ceramide and C16 ceramide in A375, G361, M14, MeWo, MNT-1, and SK-MEL-28 melanoma cells. ARN14988 also reduces growth of A375 and G361 melanoma cells (EC50s = 41.8 and 67.7 μM, respectively). | |||
T37056 |
D-erythro-MAPP
|
Others | Others |
D-erythro-MAPP is a derivative of ceramide and an inhibitor of alkaline ceramidase (Ki = 2-13 μM; IC50 = 1-5 μM). It is selective for alkaline ceramidase over acid ceramidase (IC50 = >500 μM) as well as the serine/threonine protein phosphatase CAPP at concentrations up to 10 μM. D-erythro-MAPP increases intracellular ceramide levels, induces cell cycle arrest at the G0/G1 phase, and inhibits growth of HL-60 promyelocytic leukemia cells in a time- and concentration-dependent manner. | |||
T68441 |
SABRAC
|
Others | Others |
SABRAC inhibits acid ceramidase in PC3 MC metastatic prostate cancer cells (IC50 = <1 µM), as well as induces accumulation of ceramides in the same cells. | |||
T11835 |
LCL521
|
Others; Phospholipase | Metabolism; Others |
LCL521 能抑制溶酶体酸性鞘磷脂酶(ASMase)。LCL521 是一种酸性神经酰胺酶(ACDase)抑制剂。 | |||
T22069 |
D-NMAPPD
|
Others | Others |
D-NMAPPD ((1R,2R)-B13) 是一种酸性神经酰胺酶 (acid ceramidase) 抑制剂。D-NMAPPD 通过增强神经酰胺的内源性产生来调节 NMDA 受体特性。D-NMAPPD 具有肠癌治疗的潜力。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-00880 |
ASAH1 Protein, Human, Recombinant (His & SUMO)
AC,Acid CDase,HSD33,Acylsphingosine deacylase,N-acy... |
Human | E. coli |
ASAH1 Protein, Human, Recombinant (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 58.7 kDa and the accession number is Q13510. | |||
TMPH-02490 |
ASAH1 Protein, Mouse, Recombinant (GST & His & Myc)
Acid CDase,HSD-33,Acid ceramidase... |
Mouse | E. coli |
ASAH1 Protein, Mouse, Recombinant (GST & His & Myc) is expressed in E. coli expression system with N-10XHis-GST and C-Myc tag. The predicted molecular weight is 43.8 kDa and the accession number is Q9WV54. | |||
TMPY-05099 |
GBA/glucocerebrosidase Protein, Human, Recombinant (His)
glucosidase, β, acid,GLUC,GCB,GBA1,glucosidase, bet... |
Human | HEK293 Cells |
Mutations in the GBA gene, encoding the lysosomal hydrolase glucocerebrosidase (GCase), are the most common known genetic risk factor for Parkinson's disease (PD) and dementia with Lewy bodies (DLB). ASAH1 (acid ceramidase 1) and GBA2 (glucocerebrosidase 2) enzymes that mediate glucosylsphingosine production and metabolism are attractive therapeutic targets for treating mutant GBA-associated PD. |